Brief Therapeutic Update from PES Drugs and Therapeutics Committee
(THYQUIDITYTM)
THYQUIDITYTM is a liquid levothyroxine preparation that is FDA approved for (i) treatment of congenital or acquired forms of primary, secondary and tertiary hypothyroidism, and (ii) pituitary thyrotropin suppression as an adjunct therapy in thyrotropin-dependent well-differentiated thyroid cancer (1). Safety and efficacy data for THYQUIDITYTM in pediatric patients are derived from prior trials of its reference product Synthroid® (levothyroxine sodium) tablets (see below) (1,2,3). The other liquid levothyroxine preparation commercially available for treatment of hypothyroidism is Tirosint®-SOL (4).
